Clinical characteristics and their statistical tests between the male and female groups in the TCGA LUAD. Chi-squared and Wilcoxon rank-sum tests were employed for categorical and continuous variables, respectively. Each PSG gene was categorized into two groups with (+)/without (−) gene expression. IQR: Interquartile.
| Variable . | Status . | Male (N = 235) . | Female (N = 271) . | p-value . |
|---|---|---|---|---|
| Median age (IQR) (Years) | 66 (59–72) | 66 (59–73) | 0.9844 | |
| Race | Black or African American | 23 | 29 | 0.1227 |
| White | 173 | 215 | ||
| Other races | 4 | 5 | ||
| NA | 35 | 22 | ||
| Stage | I | 113 | 158 | 0.1159 |
| II | 66 | 54 | ||
| III | 37 | 44 | ||
| IV | 14 | 12 | ||
| NA | 5 | 3 | ||
| Survival status at last follow-up | Alive | 148 | 175 | 0.7093 |
| Dead | 87 | 96 | ||
| Median follow-up (IQR) (Months) | 20.5 (10.5–35.4) | 21.6 (14.7–37.5) | 0.2471 | |
| PSG1 | Expression (+) | 47 | 61 | 0.4921 |
| No expression (−) | 188 | 210 | ||
| PSG2 | Expression (+) | 15 | 14 | 0.5570 |
| No expression (−) | 220 | 257 | ||
| PSG3 | Expression (+) | 66 | 69 | 0.5057 |
| No expression (−) | 169 | 202 | ||
| PSG4 | Expression (+) | 60 | 69 | 1.0000 |
| No expression (−) | 175 | 202 | ||
| PSG5 | Expression (+) | 46 | 47 | 0.5179 |
| No expression (−) | 189 | 224 | ||
| PSG6 | Expression (+) | 36 | 38 | 0.6801 |
| No expression (−) | 199 | 233 | ||
| PSG7 | Expression (+) | 11 | 9 | 0.4337 |
| No expression (−) | 224 | 262 | ||
| PSG8 | Expression (+) | 28 | 40 | 0.3493 |
| No expression (−) | 207 | 231 | ||
| PSG9 | Expression (+) | 50 | 59 | 0.8933 |
| No expression (−) | 185 | 212 | ||
| PSG11 | Expression (+) | 10 | 11 | 0.9128 |
| No expression (−) | 225 | 260 |
| Variable . | Status . | Male (N = 235) . | Female (N = 271) . | p-value . |
|---|---|---|---|---|
| Median age (IQR) (Years) | 66 (59–72) | 66 (59–73) | 0.9844 | |
| Race | Black or African American | 23 | 29 | 0.1227 |
| White | 173 | 215 | ||
| Other races | 4 | 5 | ||
| NA | 35 | 22 | ||
| Stage | I | 113 | 158 | 0.1159 |
| II | 66 | 54 | ||
| III | 37 | 44 | ||
| IV | 14 | 12 | ||
| NA | 5 | 3 | ||
| Survival status at last follow-up | Alive | 148 | 175 | 0.7093 |
| Dead | 87 | 96 | ||
| Median follow-up (IQR) (Months) | 20.5 (10.5–35.4) | 21.6 (14.7–37.5) | 0.2471 | |
| PSG1 | Expression (+) | 47 | 61 | 0.4921 |
| No expression (−) | 188 | 210 | ||
| PSG2 | Expression (+) | 15 | 14 | 0.5570 |
| No expression (−) | 220 | 257 | ||
| PSG3 | Expression (+) | 66 | 69 | 0.5057 |
| No expression (−) | 169 | 202 | ||
| PSG4 | Expression (+) | 60 | 69 | 1.0000 |
| No expression (−) | 175 | 202 | ||
| PSG5 | Expression (+) | 46 | 47 | 0.5179 |
| No expression (−) | 189 | 224 | ||
| PSG6 | Expression (+) | 36 | 38 | 0.6801 |
| No expression (−) | 199 | 233 | ||
| PSG7 | Expression (+) | 11 | 9 | 0.4337 |
| No expression (−) | 224 | 262 | ||
| PSG8 | Expression (+) | 28 | 40 | 0.3493 |
| No expression (−) | 207 | 231 | ||
| PSG9 | Expression (+) | 50 | 59 | 0.8933 |
| No expression (−) | 185 | 212 | ||
| PSG11 | Expression (+) | 10 | 11 | 0.9128 |
| No expression (−) | 225 | 260 |
Clinical characteristics and their statistical tests between the male and female groups in the TCGA LUAD. Chi-squared and Wilcoxon rank-sum tests were employed for categorical and continuous variables, respectively. Each PSG gene was categorized into two groups with (+)/without (−) gene expression. IQR: Interquartile.
| Variable . | Status . | Male (N = 235) . | Female (N = 271) . | p-value . |
|---|---|---|---|---|
| Median age (IQR) (Years) | 66 (59–72) | 66 (59–73) | 0.9844 | |
| Race | Black or African American | 23 | 29 | 0.1227 |
| White | 173 | 215 | ||
| Other races | 4 | 5 | ||
| NA | 35 | 22 | ||
| Stage | I | 113 | 158 | 0.1159 |
| II | 66 | 54 | ||
| III | 37 | 44 | ||
| IV | 14 | 12 | ||
| NA | 5 | 3 | ||
| Survival status at last follow-up | Alive | 148 | 175 | 0.7093 |
| Dead | 87 | 96 | ||
| Median follow-up (IQR) (Months) | 20.5 (10.5–35.4) | 21.6 (14.7–37.5) | 0.2471 | |
| PSG1 | Expression (+) | 47 | 61 | 0.4921 |
| No expression (−) | 188 | 210 | ||
| PSG2 | Expression (+) | 15 | 14 | 0.5570 |
| No expression (−) | 220 | 257 | ||
| PSG3 | Expression (+) | 66 | 69 | 0.5057 |
| No expression (−) | 169 | 202 | ||
| PSG4 | Expression (+) | 60 | 69 | 1.0000 |
| No expression (−) | 175 | 202 | ||
| PSG5 | Expression (+) | 46 | 47 | 0.5179 |
| No expression (−) | 189 | 224 | ||
| PSG6 | Expression (+) | 36 | 38 | 0.6801 |
| No expression (−) | 199 | 233 | ||
| PSG7 | Expression (+) | 11 | 9 | 0.4337 |
| No expression (−) | 224 | 262 | ||
| PSG8 | Expression (+) | 28 | 40 | 0.3493 |
| No expression (−) | 207 | 231 | ||
| PSG9 | Expression (+) | 50 | 59 | 0.8933 |
| No expression (−) | 185 | 212 | ||
| PSG11 | Expression (+) | 10 | 11 | 0.9128 |
| No expression (−) | 225 | 260 |
| Variable . | Status . | Male (N = 235) . | Female (N = 271) . | p-value . |
|---|---|---|---|---|
| Median age (IQR) (Years) | 66 (59–72) | 66 (59–73) | 0.9844 | |
| Race | Black or African American | 23 | 29 | 0.1227 |
| White | 173 | 215 | ||
| Other races | 4 | 5 | ||
| NA | 35 | 22 | ||
| Stage | I | 113 | 158 | 0.1159 |
| II | 66 | 54 | ||
| III | 37 | 44 | ||
| IV | 14 | 12 | ||
| NA | 5 | 3 | ||
| Survival status at last follow-up | Alive | 148 | 175 | 0.7093 |
| Dead | 87 | 96 | ||
| Median follow-up (IQR) (Months) | 20.5 (10.5–35.4) | 21.6 (14.7–37.5) | 0.2471 | |
| PSG1 | Expression (+) | 47 | 61 | 0.4921 |
| No expression (−) | 188 | 210 | ||
| PSG2 | Expression (+) | 15 | 14 | 0.5570 |
| No expression (−) | 220 | 257 | ||
| PSG3 | Expression (+) | 66 | 69 | 0.5057 |
| No expression (−) | 169 | 202 | ||
| PSG4 | Expression (+) | 60 | 69 | 1.0000 |
| No expression (−) | 175 | 202 | ||
| PSG5 | Expression (+) | 46 | 47 | 0.5179 |
| No expression (−) | 189 | 224 | ||
| PSG6 | Expression (+) | 36 | 38 | 0.6801 |
| No expression (−) | 199 | 233 | ||
| PSG7 | Expression (+) | 11 | 9 | 0.4337 |
| No expression (−) | 224 | 262 | ||
| PSG8 | Expression (+) | 28 | 40 | 0.3493 |
| No expression (−) | 207 | 231 | ||
| PSG9 | Expression (+) | 50 | 59 | 0.8933 |
| No expression (−) | 185 | 212 | ||
| PSG11 | Expression (+) | 10 | 11 | 0.9128 |
| No expression (−) | 225 | 260 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
